PF-Atlas › Clinical Trials › NCT03133299
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Glucocorticoids · Phase 2
Registry ID
NCT03133299
Phase
Phase 2
Status
Completed
Drug / intervention
Glucocorticoids
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Start
2016-12-01
Enrollment
30
Locations
1
About this trial
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. Recently anti-Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 responses and decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role of vitamin D in treating ABPA.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03133299 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.